Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292213 | 0.84 | CYP2C19 (0.44) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL31292617 | 0.82 | NNMT (0.44) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38654859 | 0.82 | CYP2C19 (0.40) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL31292247 | 0.81 | LMNA (0.43) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL31292581 | 0.81 | CYP2C19 (0.39) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38654843 | 0.79 | CYP2C19 (0.38) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38654889 | 0.78 | CYP2C19 (0.37) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38655191 | 0.78 | CYP2C19 (0.37) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38655652 | 0.77 | CYP2C19 (0.36) | CYP2C19CNR2CNR1PLCG1KCNN4 | |
| SCHEMBL38656582 | 0.77 | CYP2C19 (0.36) | CYP2C19CNR2CNR1PLCG1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP2C19 4814/4885CNR2 1899/4885CNR1 2484/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CYP2C19 4816/4885CNR2 1908/4885CNR1 2491/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP2C19 4814/4885CNR2 1899/4885CNR1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.